Table 2 Clinical characteristics of patients based on polyglutamylation status
From: Clinical significance of polyglutamylation in primary central nervous system lymphoma
|  | Polyglutamylation (n = 43) | Non polyglutamylation (n = 39) | p |
|---|---|---|---|
Age (y) | |||
 Median (range) | 68 (37–84) | 67 (46–86) | 0.70* |
Sex (# of pts) | |||
 Male/ Female | 27/ 16 | 19/ 20 | 0.20** |
KPS (%) | |||
 Median (range) | 50 (20–100) | 40 (20–100) | 0.43* |
(# of pts) High (≥70) / Low (≤60) | 12/ 31 | 10/ 29 | 0.82** |
MSKCC prognostic score | |||
 Median (range) | 3 (1–3) | 3 (1–3) | 0.76* |
Cell of origin | |||
 GCB/ non-GCB | 17/ 24a | 7/ 32 | 0.022** |
LDH (# of pts) | |||
 High/ Normal range | 16/ 27 | 15/ 24 | 0.91** |
Location (# of pts) | |||
 Deep/ No | 35/ 8 | 27/ 12 | 0.20** |